Scarlet Fever (ICD-11: 1B50) - Complete Coding and Diagnostic Guide

1. Introduction

Scarlet fever is an acute infectious disease that represents an important diagnostic and therapeutic challenge in contemporary clinical practice. Caused by pyrogenic exotoxins produced by Streptococcus pyogenes (beta-hemolytic streptococcus Group A), this condition is distinguished by its characteristic presentation that combines systemic symptoms with specific cutaneous and oropharyngeal manifestations.

Historically considered one of the major causes of childhood morbidity and mortality, scarlet fever had its impact significantly reduced with the advent of antibiotics. However, it remains a clinically relevant condition, especially in pediatric populations, where most cases occur between 5 and 15 years of age. The disease remains endemic in many regions of the world, with occasional outbreaks in crowded settings such as schools and daycare centers.

The importance of accurate coding of scarlet fever in the ICD-11 system transcends merely administrative issues. Appropriate coding enables effective epidemiological tracking, facilitating the identification of outbreaks, monitoring of antimicrobial resistance trends, and appropriate allocation of public health resources. Furthermore, correct documentation is fundamental for appropriate clinical follow-up, since scarlet fever can progress with serious complications, including acute rheumatic fever and post-streptococcal glomerulonephritis.

The code 1B50 was specifically designated to capture this distinct clinical entity, differentiating it from other streptococcal infections that do not present the characteristic exotoxigenic component. Understanding when and how to apply this code correctly is essential for healthcare professionals involved in patient care, documentation, and case management.

2. Correct ICD-11 Code

ICD-11 Code: 1B50

Description: Scarlet fever

Parent Category: Some staphylococcal or streptococcal diseases

Complete Official Definition:

Scarlet fever is a disease caused by exotoxins released by beta-hemolytic streptococci of Group A. It is most commonly associated with streptococcal pharyngitis or tonsillitis. Most cases occur in childhood. It is characterized by sudden onset of sore throat, headache, high fever, anorexia, nausea, and malaise. The rash appears 12 to 48 hours after fever onset as a confluent erythema with rough texture initially involving the neck, chest, and axillae, but soon becoming generalized. The rash blanches with pressure, spares the skin around the mouth ("perioral pallor"), and has been compared to "sunburn with goosebumps." In the mouth there are signs not only of streptococcal pharyngitis and tonsillitis, but also of glossitis (strawberry tongue). The rash begins to disappear three to four days after onset, with desquamation (peeling) affecting particularly the hands and feet.

This specific code recognizes scarlet fever as a distinct entity within the spectrum of streptococcal diseases, differentiating it by the mandatory presence of the characteristic exotoxin-mediated rash. Appropriate coding requires not only confirmation of streptococcal infection, but also documentation of the typical dermatological manifestations that define this clinical syndrome.

3. When to Use This Code

Code 1B50 should be used in specific clinical situations where all diagnostic elements of scarlet fever are present. Below, we present detailed practical scenarios:

Scenario 1: Child with Complete Classic Presentation

A 7-year-old child presents to the health service with high fever (39-40°C) starting 24 hours ago, accompanied by intense odynophagia and food refusal. On physical examination, hyperemic pharynx with tonsillar exudate is observed, tongue with prominent papillae (strawberry tongue), and generalized erythematous rash with rough texture to palpation, starting on the trunk and neck, with evident perioral pallor. Rapid test for Group A Streptococcus is positive. This is the classic scenario for using code 1B50.

Scenario 2: Adolescent with Typical Course

A 12-year-old adolescent was initially diagnosed with pharyngitis and, 36 hours after symptom onset, develops characteristic "sandpaper" rash that extends from the neck to the trunk and extremities, initially sparing palms and soles. Oropharyngeal culture confirms Streptococcus pyogenes. In this case, even though the initial diagnosis was pharyngitis, the correct code becomes 1B50 when the characteristic rash manifests.

Scenario 3: Patient with Post-Exanthem Desquamation

A 6-year-old child is brought for follow-up consultation after treatment for febrile illness and rash. At the time of evaluation, characteristic desquamation is present on fingers and toes ("glove" and "sock" desquamation), confirming retrospective diagnosis of scarlet fever. Code 1B50 remains appropriate even in this late phase of the disease.

Scenario 4: School Outbreak with Laboratory Confirmation

During investigation of an outbreak in a school setting, multiple children present with fever, pharyngitis, and typical rash, with microbiological confirmation of erythrogenic toxin-producing Streptococcus pyogenes. Each confirmed case should receive code 1B50, facilitating epidemiological tracking.

Scenario 5: Adult with Atypical but Confirmed Presentation

Although less common, a 28-year-old adult presents with pharyngitis followed by rash with typical characteristics of scarlet fever, confirmed by culture and streptococcal toxin detection. Despite the atypical age, the presence of all diagnostic criteria justifies the use of code 1B50.

Scenario 6: Patient with Associated Complications

A child diagnosed with scarlet fever subsequently develops signs of post-streptococcal glomerulonephritis. The primary code remains 1B50, with additional codes for renal complications, clearly establishing the causal relationship between the exotoxigenic streptococcal infection and its sequelae.

4. When NOT to Use This Code

It is essential to understand the situations in which code 1B50 should not be applied, avoiding coding errors that may compromise epidemiological data and clinical management:

Staphylococcal Scarlet Fever (Code: 1B42)

When the scarlatiniform rash is caused by Staphylococcus aureus producing toxins (and not by Group A streptococcus), the correct code is 1B42. This distinction is crucial, as the etiological agent, treatment, and prognosis differ significantly. Differentiation requires microbiological culture or specific molecular tests.

Streptococcal Pharyngitis Without Rash (Code: 1B51)

Patients with pharyngitis or tonsillitis confirmed by Group A streptococcus, but without development of the characteristic cutaneous rash, should receive code 1B51. The absence of the exanthematous component indicates that, although there is streptococcal infection, there is no production of or response to the pyrogenic exotoxins that define scarlet fever.

Other Causes of Scarlatiniform Rash

Various conditions can mimic the scarlet fever rash, including drug reactions, Kawasaki disease, toxic shock syndrome, and viral exanthems. Without confirmation of Group A streptococcal infection and presence of all diagnostic criteria, code 1B50 should not be used. Appropriate diagnostic investigation, including microbiological tests and detailed clinical evaluation, is essential before coding.

Streptococcal Infections at Other Sites

Infections caused by Group A streptococcus at locations other than the oropharynx (such as cellulitis, erysipelas, impetigo, or invasive infections) have specific codes and should not be coded as 1B50, even if the etiological agent is the same. Scarlet fever specifically requires pharyngeal focus with toxigenic dissemination.

Asymptomatic Carriers

Individuals who present with positive culture for Group A streptococcus without clinical manifestations should not receive code 1B50. Carrier status does not represent active disease and requires a differentiated approach.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

Correct coding of scarlet fever begins with rigorous diagnostic confirmation. Essential criteria include:

Mandatory Clinical Manifestations:

Fever of sudden onset, usually high (above 38.5°C)
Pharyngitis or tonsillitis with hyperemia and frequently exudate
Characteristic skin eruption (scarlatiniform exanthem) with rough texture
Perioral pallor (Filatov sign)
Strawberry tongue (initially white, then red with prominent papillae)

Laboratory Confirmation: Diagnosis can be confirmed through:

Rapid streptococcal antigen test (high specificity, variable sensitivity)
Oropharyngeal culture (gold standard, identifies Streptococcus pyogenes)
Serological tests (antistreptolysin O - ASO, anti-DNAse B) in retrospective cases
Molecular tests (PCR) when available

Temporal Assessment: Documenting the temporal sequence is crucial: the eruption typically appears 12 to 48 hours after fever onset and pharyngeal symptoms, starting on the upper trunk and neck, generalizing within 24 hours.

Step 2: Verify Specifiers

Although code 1B50 does not have mandatory extensions in the ICD-11 system, clinical documentation should include:

Severity:

Mild: minimal systemic symptoms, discrete eruption
Moderate: high fever, typical generalized eruption, significant systemic symptoms
Severe: significant systemic toxicity, suppurative or non-suppurative complications

Duration and Evolution: Document the day of illness at the time of evaluation, as clinical characteristics evolve: the typical eruption lasts 3-4 days, followed by desquamation that may persist for 2-3 weeks.

Associated Complications: Identify and code separately complications such as otitis media, sinusitis, peritonsillar abscess (suppurative complications) or acute rheumatic fever and glomerulonephritis (non-suppurative complications).

Step 3: Differentiate from Other Codes

Differentiation from Acute Rheumatic Fever: Rheumatic fever is a late non-suppurative complication of streptococcal infection, occurring 2-4 weeks after initial infection. It is characterized by Jones criteria (carditis, migratory polyarthritis, chorea, erythema marginatum, subcutaneous nodules). When a patient develops rheumatic fever after scarlet fever, both conditions should be coded, with rheumatic fever as the principal diagnosis at the time of complication.

Differentiation from Streptococcal Pharyngitis (1B51): The fundamental distinction is the presence of characteristic skin eruption in scarlet fever. Streptococcal pharyngitis without exanthem receives code 1B51. If a patient initially coded as 1B51 develops typical eruption within 48 hours, the code should be updated to 1B50.

Differentiation from Group A Streptococcal Meningitis (1B53): Group A streptococcal meningitis is a severe invasive infection of the central nervous system, with clinical presentation dominated by meningeal signs, altered consciousness, and cerebrospinal fluid pleocytosis. Although caused by the same agent, it represents a completely distinct clinical syndrome from scarlet fever, with different pathophysiology, treatment, and prognosis.

Step 4: Required Documentation

Checklist of Mandatory Information:

□ Date of symptom onset □ Maximum recorded temperature □ Detailed description of skin eruption (location, texture, progression) □ Presence or absence of perioral pallor □ Characteristics of tongue (white or red phase) □ Pharyngeal findings (hyperemia, exudate, cervical adenopathy) □ Results of microbiological tests (type, date, result) □ Treatment instituted (antibiotic, dose, duration) □ Presence of complications □ Contact with similar cases (epidemiological context)

Appropriate Medical Record Documentation: Documentation should allow any subsequent healthcare professional to clearly understand why the diagnosis of scarlet fever was established. Descriptions such as "rough-textured skin eruption, starting on the trunk, with perioral pallor" are superior to vague terms such as "generalized rash".

6. Complete Practical Example

Detailed Clinical Case

Initial Presentation:

Sofia, 8 years old, previously healthy, is brought to the pediatric emergency department by her parents with a history of high fever (39.5°C) that started 30 hours ago, accompanied by severe sore throat, difficulty swallowing, and food refusal. In the last 12 hours, the parents noticed the appearance of "red spots" on the child's neck and chest, which spread rapidly.

Complementary History:

The child also complains of headache and nausea since the onset of symptoms. There was no vomiting. The mother reports that two other children from the same classroom presented with a similar condition the previous week. There is no history of recent medication use or exposure to known allergens. The vaccination schedule is up to date.

Physical Examination:

General condition: irritable child, febrile to touch, hydrated
Vital signs: Axillary temperature 39.2°C, HR 120 bpm, RR 24 breaths/min, BP 95/60 mmHg
Oropharynx: intense pharyngeal hyperemia, enlarged tonsils (grade 3) with punctate bilateral exudate, edematous uvula
Tongue: white coating with prominent red papillae (white strawberry tongue)
Skin: confluent erythematous rash, rough to touch (sandpaper texture), distributed on neck, chest, axillae, abdomen, and root of limbs. The rash blanches with finger pressure. Prominent perioral pallor (skin around the mouth spared by the exanthem). No involvement of palms or soles.
Lymph nodes: bilateral anterior cervical lymphadenopathy, mobile lymph nodes, tender to palpation, the largest measuring approximately 2 cm
Cardiopulmonary auscultation: no abnormalities
Abdomen: no hepatosplenomegaly

Evaluation Performed:

Given the characteristic clinical presentation, the following were requested:

Rapid test for streptococcal antigen detection: POSITIVE
Oropharyngeal culture: collected (result pending)
Complete blood count: leukocytosis with left shift (white blood cells 16,500/mm³, neutrophils 78%)
C-reactive protein: elevated (8.5 mg/dL)

Diagnostic Reasoning:

The combination of high fever with sudden onset, exudative pharyngitis, strawberry tongue, characteristic skin rash with rough texture and perioral pallor, cervical lymphadenopathy, and positive rapid test for Group A Streptococcus establishes the diagnosis of scarlet fever. The epidemiological context of similar cases in the school reinforces the diagnosis.

Management:

Treatment initiated with amoxicillin 50 mg/kg/day, divided into 2 doses, for 10 days
Antipyretic (acetaminophen) for symptomatic control
Guidance on hydration and soft diet
School absence for 24 hours after antibiotic initiation
Follow-up in 48-72 hours for reassessment or sooner if clinical deterioration
Guidance on warning signs for complications

Step-by-Step Coding

Criteria Analysis:

✓ High fever with sudden onset: PRESENT ✓ Streptococcal pharyngitis: PRESENT (clinical presentation + positive test) ✓ Characteristic skin rash: PRESENT (rough texture, typical distribution) ✓ Perioral pallor: PRESENT ✓ Strawberry tongue: PRESENT ✓ Appropriate temporal sequence: PRESENT (rash 18 hours after fever)

Code Selected: 1B50 - Scarlet fever

Complete Justification:

Code 1B50 is the correct code because the patient presents all essential diagnostic elements of scarlet fever: confirmed streptococcal infection (positive rapid test) with systemic manifestations (fever, malaise) and the characteristic exanthematous component mediated by exotoxins. The presence of perioral pallor and strawberry tongue are pathognomonic signs that reinforce the diagnosis. The skin rash with rough texture distinguishes this condition from simple streptococcal pharyngitis (1B51).

Complementary Codes:

In this specific case, there is no need for additional codes at the time of initial presentation. Should the patient develop complications (such as otitis media, glomerulonephritis, or acute rheumatic fever), additional codes would be necessary. Clinical follow-up should include evaluation for possible late sequelae in the following weeks.

Medical Record Documentation:

"Female patient, 8 years old, with scarlet fever (ICD-11: 1B50) characterized by high fever, exudative pharyngitis, strawberry tongue, and typical scarlatiniform rash with perioral pallor. Rapid test for Group A Streptococcus positive. Appropriate antimicrobial treatment initiated. Surveillance advised for suppurative and non-suppurative complications."

7. Related Codes and Differentiation

Within the Same Category

Acute Rheumatic Fever

When to use: Acute rheumatic fever is a late non-suppurative complication of Group A streptococcal infection, typically occurring 2-4 weeks after the initial infection. It should be coded when the patient meets the revised Jones criteria, including major manifestations (carditis, polyarthritis, chorea, erythema marginatum, subcutaneous nodules) and minor manifestations (fever, arthralgia, elevation of acute phase reactants, prolongation of PR interval).

Main difference: Scarlet fever (1B50) is the acute infection with toxigenic cutaneous manifestations, whereas acute rheumatic fever is a late immunomediated sequela. A patient may have both conditions coded sequentially: first 1B50 during the acute infection, and subsequently the acute rheumatic fever code if this complication develops.

1B51: Streptococcal Pharyngitis

When to use: This code is appropriate for patients with confirmed Group A streptococcal pharyngeal infection but without development of the characteristic scarlatiniform rash of scarlet fever. It includes cases of isolated streptococcal pharyngitis or tonsillitis.

Main difference: The presence or absence of the scarlatiniform rash is the crucial differentiating element. Streptococcal pharyngitis (1B51) may progress to scarlet fever (1B50) if the rash develops, at which point the code should be updated. Both conditions share the same etiologic agent and antimicrobial treatment, but scarlet fever indicates production of pyrogenic exotoxins and host immune response.

1B53: Meningitis due to Streptococcus

When to use: Reserved for cases of central nervous system infection due to streptococcus, confirmed by cerebrospinal fluid analysis showing pleocytosis, hyperproteinorrhachia, hypoglycorrhachia, and agent identification (culture, antigen, or PCR).

Main difference: Streptococcal meningitis is a severe invasive infection with CNS involvement, presenting with fever, severe headache, neck stiffness, altered consciousness, and meningeal signs. Although the agent may be the same (including Group A streptococcus), the clinical syndrome, severity, treatment (high-dose intravenous antibiotic therapy), and prognosis differ radically from scarlet fever. They are mutually exclusive conditions in terms of primary coding.

Differential Diagnoses

Kawasaki Disease: May present with fever, cutaneous rash, conjunctival hyperemia, mucosal and extremity changes. It is differentiated by the absence of streptococcal confirmation, presence of non-exudative conjunctivitis, extremity changes (edema, erythema, periungual desquamation), and risk of coronary aneurysms.

Streptococcal Toxic Shock Syndrome: Severe invasive infection with shock, multiorgan failure, and cutaneous rash. It is differentiated by extreme systemic severity, hypotension, soft tissue involvement, and high mortality.

Viral Exanthems: Various viral infections (measles, rubella, erythema infectiosum, exanthem subitum) may cause cutaneous rashes in children. The absence of streptococcal confirmation, specific rash characteristics, and clinical context allow for differentiation.

Drug Reactions: Drug-induced rashes may mimic scarlet fever. History of recent medication introduction and absence of evidence of streptococcal infection are differentiating elements.

8. Differences with ICD-10

Equivalent ICD-10 Code: A38 - Scarlet fever

Main Changes in ICD-11:

The transition from ICD-10 to ICD-11 brought significant structural changes in the organization of infectious diseases. In ICD-10, scarlet fever was coded simply as A38, a single code without subdivisions. In ICD-11, scarlet fever receives the code 1B50 and is integrated into a more complex hierarchical structure within the category "Some staphylococcal or streptococcal diseases".

Structure and Organization:

ICD-11 offers greater granularity and context for streptococcal diseases, allowing better differentiation between various clinical manifestations caused by the same agent. The alphanumeric structure of ICD-11 (1B50) replaces the ICD-10 system (A38), reflecting a fundamental reorganization of the taxonomy of infectious diseases.

Expanded Definitions:

A significant change is the inclusion of more detailed and specific clinical definitions in ICD-11. While ICD-10 offered minimal descriptions, ICD-11 provides expanded diagnostic criteria, including the characteristic description of "sunburn with chills", perioral pallor, strawberry tongue, and the temporal pattern of rash and desquamation.

Practical Impact:

For healthcare professionals, the change from A38 to 1B50 requires updating information systems, training coding teams, and reviewing institutional protocols. The greater specificity of ICD-11 can improve the quality of epidemiological data, allowing more precise analyses of trends, outbreaks, and intervention effectiveness. Billing and reimbursement systems will need to adapt to the new codes, and interoperability between systems using ICD-10 and ICD-11 must be carefully managed during the transition period.

Backward Compatibility:

Organizations that maintain historical records should establish correspondence tables between A38 (ICD-10) and 1B50 (ICD-11) to allow consistent longitudinal analyses. Most health information systems offer mapping tools to facilitate this transition, although manual review may be necessary in complex cases.

9. Frequently Asked Questions

1. How is the definitive diagnosis of scarlet fever made?

The diagnosis of scarlet fever is primarily clinical, based on the presence of the characteristic triad: pharyngitis, fever, and typical scarlatiniform rash. Laboratory confirmation through rapid streptococcal antigen testing or oropharyngeal culture identifies Streptococcus pyogenes, but the distinctive element is the cutaneous rash with rough texture, perioral pallor, and strawberry tongue. The combination of characteristic clinical findings with microbiological confirmation establishes the definitive diagnosis. In retrospective cases, elevation of antistreptolysin titers (ASO, anti-DNAse B) may aid in confirmation.

2. Is treatment available in public health systems?

Yes, scarlet fever treatment is widely available in public health systems globally. First-line antibiotics (penicillin or amoxicillin) are low-cost medications included in essential medicine lists of international health organizations. Treatment is outpatient in most cases, with a duration of 10 days. Alternatives for penicillin-allergic patients (such as macrolides or cephalosporins) are also generally available. Access to appropriate treatment is fundamental for prevention of serious complications.

3. How long does treatment last and what is the prognosis?

Standard antimicrobial treatment for scarlet fever lasts 10 days, regardless of early clinical improvement. Fever typically resolves within 24-48 hours after antibiotic initiation, and the rash disappears in 3-4 days, followed by desquamation that may persist for 2-3 weeks. The prognosis is excellent with appropriate treatment, with complete recovery in the vast majority of cases. Complications are rare when treatment is initiated early, but follow-up is important to detect possible late sequelae such as acute rheumatic fever or glomerulonephritis, which may occur weeks after the initial infection.

4. Can this code be used in medical certificates and work/school documentation?

Yes, code 1B50 can and should be used in medical certificates when appropriate. Scarlet fever justifies absence from school or work activities for at least 24 hours after initiation of antimicrobial treatment, the period after which the patient is no longer contagious. Appropriate documentation is important not only to justify individual absence, but also to alert institutions about possible outbreaks, allowing epidemiological control measures. Correct coding facilitates case tracking and implementation of public health strategies.

5. What are the main warning signs for complications?

Patients and caregivers should be instructed to seek immediate medical reevaluation if the following occur: persistent or recurrent fever after 48 hours of antibiotics, difficulty breathing, severe neck pain or asymmetry (suggesting abscess), altered level of consciousness, signs of dehydration, dark urine or decreased urine output (possible glomerulonephritis), migratory joint pain or signs of heart failure (possible acute rheumatic fever). Scheduled follow-up 2-3 weeks after acute infection allows early detection of late non-suppurative complications.

6. Does scarlet fever confer permanent immunity?

Scarlet fever does not confer complete permanent immunity. Although infection produces antibodies against the specific erythrogenic toxin produced by the infecting strain, there are multiple types of streptococcal toxins. Thus, an individual can have scarlet fever more than once if infected by strains producing different toxins. However, recurrent episodes are relatively uncommon, and subsequent infections tend to be milder due to partial cross-immunity.

7. How to differentiate scarlet fever from other rashes in febrile children?

Differentiation is based on specific characteristics: the scarlatiniform rash has a rough texture ("sandpaper"), begins on the upper trunk and neck, spares the perioral region (perioral pallor), and is accompanied by pharyngitis and strawberry tongue. Viral exanthems generally do not have rough texture, the distribution is different, and there is no typical exudative pharyngitis. Kawasaki disease presents with conjunctivitis, extremity changes, and absence of streptococcal confirmation. Drug reactions have a history of recent drug exposure. Microbiological confirmation is essential when diagnostic doubt exists.

8. Is contact tracing necessary?

Yes, close contact tracing is recommended, especially in crowded settings such as schools, daycare centers, and households. Symptomatic contacts should be evaluated and treated if streptococcal infection is confirmed. Asymptomatic contacts generally do not require prophylactic treatment, except in special situations (outbreaks in closed communities, presence of individuals at high risk for complications). Notification of cases to health authorities allows implementation of appropriate epidemiological control measures, preventing further spread and identifying outbreaks early.

Conclusion:

Appropriate coding of scarlet fever using ICD-11 code 1B50 is fundamental for accurate clinical documentation, effective epidemiological surveillance, and appropriate health resource management. Understanding the specific diagnostic criteria, the situations in which the code should or should not be applied, and its differentiation from other streptococcal conditions enables health professionals to properly document this important pediatric infectious disease. With appropriate antimicrobial treatment and adequate follow-up, the prognosis of scarlet fever is excellent, but vigilance for complications remains essential. The transition from ICD-10 to ICD-11 offers an opportunity to improve the quality of health data, benefiting both individual care and public health initiatives.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Scarlet Fever

Compartir